Loading clinical trials...

Confirmatory Study of DSP-5423P in Patients With Schizophrenia | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Confirmatory Study of DSP-5423P in Patients With Schizophrenia

NCT02287584•Sumitomo Pharma Co., Ltd.

Summary

The primary objective of the study is to evaluate the efficacy of DSP-5423P compared with placebo in patients with schizophrenia.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients who have schizophrenia diagnosed by DSM-5, diagnostic criteria
•Patients who are aged 18 years or older at informed consent
•Patient understands the objectives and procedures of the study and who provide written voluntarily consent to participate in the study, etc.

Exclusion Criteria

•Patients who fall under a contraindication listed in the blonanserin (LONASEN) package insert
•Patients with Parkinson disease
•Patients who previously received blonanserin, etc.

Locations (8)

3 Sites

Beijing, Etc., China

53 Sites

Tokyo Etc., Japan

14 Sites

Kuala Lumpur, Etc., Malaysia

9 Sites

Manila, Etc., Philippines

8 Sites

Smolensk, Etc, Russia

7 Sites

Seoul, Etc., South Korea

6 Sites

Taipei, Etc., Taiwan

8 Sites

Poltava, Etc, Ukraine

Key Dates

Start Date

December 1, 2014

Primary Completion Date

December 1, 2018

Completion Date

December 1, 2018

Last Updated

April 12, 2022

Enrollment

580

ACTUAL participants

Conditions

Schizophrenia

Interventions

DSP-5423P Placebo

DRUG

DSP-5423P 40mg

DRUG

DSP-5423P 80mg

DRUG

DSP-5423P Placebo-to-Flex

DRUG

DSP-5423P Active-to-Flex

DRUG

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 12, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Confirmatory Study of DSP-5423P in Patients With Schizophrenia

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques

Brain Stimulation to the Hippocampus in Schizophrenia